Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Theratechnologies, Inc.

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Public

Established: 1993-01-01

Employees: 114

Market Cap: $59.7M

Website: http://www.theratech.com

Clinical Trials

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting

Conditions: HIV Infections
Multi-Antiviral Resistance

Interventions: Biological: On ibalizumab treatment
Other: No ibalizumab or Pre-ibalizumab treatment

First Posted Date: 2022-05-24

Last Posted Date: 2025-05-21

Lead Sponsor: Theratechnologies

Target Recruit Count: 200

Registration Number: NCT05388474

Locations: 🇺🇸
Indiana University Health Inc., Bloomington, Indiana, United States
🇺🇸
Ruane Clinical Research, Los Angeles, California, United States
🇺🇸
Mills Clinical Research, Los Angeles, California, United States

and more 33 locations

The Visceral Adiposity Measurement and Observation Study

Completed

Conditions: HIV Lipodystrophy
BMI
HIV-Infections
NASH
Liver Fibrosis
Waist Circumference
Ectopic Fat
Liver Fat
Lipohypertrophy
Hepatic Fibrosis

Interventions: Diagnostic Test: Diagnostic Test
Drug: HIV Anti-retroviral Background Therapy

First Posted Date: 2022-05-20

Last Posted Date: 2023-11-18

Lead Sponsor: Theratechnologies

Target Recruit Count: 196

Registration Number: NCT05383456

Locations: 🇺🇸
Ruane Clinical Research, Los Angeles, California, United States
🇺🇸
AIDS Healthcare Foundation, New York, New York, United States
🇺🇸
Bliss Health, Orlando, Florida, United States

and more 2 locations

TH1902 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor
Hormone Receptor-positive Breast Cancer
Cutaneous Melanoma
Small-cell Lung Cancer
Endometrial Cancer
SORT1+ Cancers
TNBC - Triple-Negative Breast Cancer
Epithelial Ovarian Cancer
Prostate Cancer
Thyroid Cancer

Interventions: Drug: TH1902

First Posted Date: 2021-01-13

Last Posted Date: 2025-04-15

Lead Sponsor: Theratechnologies

Target Recruit Count: 70

Registration Number: NCT04706962

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
Pennsylvania Cancer Specialists Research Institute, Gettysburg, Pennsylvania, United States

and more 3 locations

Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Tesamorelin

First Posted Date: 2013-12-16

Last Posted Date: 2013-12-16

Lead Sponsor: Theratechnologies

Target Recruit Count: 18

Registration Number: NCT02012556

Locations: 🇨🇦
Anapharm Montreal, Montreal, Quebec, Canada

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Phase 4

Terminated

Conditions: Diabetic Retinopathy
HIV

Interventions: Drug: Placebo-Control
Drug: Tesamorelin

First Posted Date: 2012-05-04

Last Posted Date: 2018-09-11

Lead Sponsor: Theratechnologies

Target Recruit Count: 129

Registration Number: NCT01591902

Locations: 🇺🇸
Southwest Center for HIV/AIDS, Phoenix, Arizona, United States
🇺🇸
Spectrum Medical Group, Phoenix, Arizona, United States
🇺🇸
5P21 Rand Schrader Clinic, Los Angeles, California, United States

and more 21 locations

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

Terminated

Conditions: HIV

Interventions: Drug: Tesamorelin for injection

First Posted Date: 2012-04-18

Last Posted Date: 2018-09-11

Lead Sponsor: Theratechnologies

Target Recruit Count: 391

Registration Number: NCT01579695

Locations: 🇺🇸
Franco Felizarta, MD, Bakersfield, California, United States
🇺🇸
Pacific Coast Medical Group, Fountain Valley, California, United States
🇺🇸
University of California CARE Clinic, Los Angeles, Los Angeles, California, United States

and more 26 locations

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Placebo
Drug: Tesamorelin

First Posted Date: 2011-07-07

Last Posted Date: 2022-03-18

Lead Sponsor: Theratechnologies

Target Recruit Count: 3

Registration Number: NCT01388920

Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

First Posted Date: 2010-12-21

Last Posted Date: 2010-12-21

Lead Sponsor: Theratechnologies

Target Recruit Count: 55

Registration Number: NCT01264497

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Phase 3

Completed

Conditions: HIV Infections
Lipodystrophy

Interventions: Drug: Tesamorelin
Drug: Placebo for Tesamorelin

First Posted Date: 2008-02-06

Last Posted Date: 2022-09-30

Lead Sponsor: Theratechnologies

Target Recruit Count: 263

Registration Number: NCT00608023

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Body Positive Inc., Phoenix, Arizona, United States
🇺🇸
Somero, Michael, Indio, California, United States

and more 44 locations

TH9507 in Patients With HIV-Associated Lipodystrophy

Phase 3

Completed

Conditions: Lipodystrophy
HIV Infections

First Posted Date: 2005-07-22

Last Posted Date: 2013-11-27

Lead Sponsor: Theratechnologies

Target Recruit Count: 412

Registration Number: NCT00123253

Locations: 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸
Office of Dr. Michael Somero, Palm Springs, California, United States
🇺🇸
UCSD Medical Center, San Diego, California, United States

and more 39 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy